Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma
Objective To investigate the safety and efficacy of the induction therapy of nimotuzumab combined with PF regimen (cisplatin+5-fluorouracil) in the follow-up treatment of locally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy. Methods We included 118 patients with s...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-04-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.2031.htm |
id |
doaj-a9cf837cb5b54ec281778ea6d9b4e18e |
---|---|
record_format |
Article |
spelling |
doaj-a9cf837cb5b54ec281778ea6d9b4e18e2020-11-25T02:05:21ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782019-04-0146435836210.3971/j.issn.1000-8578.2019.18.20318578.2019.18.2031Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal CarcinomaLU Ying0CHEN Dagui1LIANG Jinhui2GAO Jianquan3LUO Zhanxiong4WANG Rensheng5LIU Wenqi6HUANG Changjie7NING Xuejian8LIU Meilian9HUANG Haixin10Oncology Department, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, ChinaOncology Department, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, ChinaRadiotherapy Department, Wuzhou Red Cross Hospital, Wuzhou 546002, ChinaRadiotherapy Department, Wuzhou Red Cross Hospital, Wuzhou 546002, ChinaRadiotherapy Department, Liuzhou People's Hospital, Liuzhou 545001, ChinaRadiotherapy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, ChinaRadiotherapy Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530037, ChinaRadiotherapy Department, The Second Nanning People's Hospital, Nanning 530031, ChinaOncology Department, Liuzhou Traditional Chinese Medical Hospital, Liuzhou 545001, ChinaRadiotherapy Department, The Affiliated Hospital of Guilin Medical University, Guilin 541001, ChinaOncology Department, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, ChinaObjective To investigate the safety and efficacy of the induction therapy of nimotuzumab combined with PF regimen (cisplatin+5-fluorouracil) in the follow-up treatment of locally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy. Methods We included 118 patients with stage Ⅲ-Ⅳa nasopharyngeal carcinoma, 58 cases in NPF group (induction therapy of nimotuzumab combined with PF regimen) and 60 cases in TPF group (induction chemotherapy of docetaxel, cisplatin and fluorouracil regimen). After two cycles of induction therapy, all patients received concurrent cisplatin and intensity-modulated radiotherapy (IMRT), and the safety and short-term efficacy of the two groups were compared. Results Compared with TPF group, NPF induction therapy was more effective for cervical lymph nodes (P=0.036); however, there was no significant difference in the effect of induction therapy on primary lesions, overall effect or the immediate effect of the whole course of treatment(P > 0.05). Compared with TPF group, neutropenia and gastrointestinal reaction in the NPF group was significantly improved during the induction therapy (P=0.028, P=0.049); gastrointestinal reaction, oral mucositis and radiation dermatitis in the NPF group were significantly improved during the concurrent chemoradiotherapy (P=0.038, P=0.041, P=0.035). Conclusion For locally advanced nasopharyngeal carcinoma patients received cisplatin concurrent IMRT, the induction therapy of nimotuzumab combined with PF regimen have a better lymph node remission rate and mild adverse reactions. Patients had better tolerance in subsequent concurrent chemoradiotherapy, but the long-term efficacy requires further follow-up observation.http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.2031.htmnasopharyngeal carcinomaegfr monoclonal antibodyinduction treatmentefficacyadverse reaction |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
LU Ying CHEN Dagui LIANG Jinhui GAO Jianquan LUO Zhanxiong WANG Rensheng LIU Wenqi HUANG Changjie NING Xuejian LIU Meilian HUANG Haixin |
spellingShingle |
LU Ying CHEN Dagui LIANG Jinhui GAO Jianquan LUO Zhanxiong WANG Rensheng LIU Wenqi HUANG Changjie NING Xuejian LIU Meilian HUANG Haixin Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma Zhongliu Fangzhi Yanjiu nasopharyngeal carcinoma egfr monoclonal antibody induction treatment efficacy adverse reaction |
author_facet |
LU Ying CHEN Dagui LIANG Jinhui GAO Jianquan LUO Zhanxiong WANG Rensheng LIU Wenqi HUANG Changjie NING Xuejian LIU Meilian HUANG Haixin |
author_sort |
LU Ying |
title |
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma |
title_short |
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma |
title_full |
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma |
title_fullStr |
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma |
title_full_unstemmed |
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma |
title_sort |
multi-center clinical study of nimotuzumab combined with pf regimen in induction treatment of locally advanced nasopharyngeal carcinoma |
publisher |
Magazine House of Cancer Research on Prevention and Treatment |
series |
Zhongliu Fangzhi Yanjiu |
issn |
1000-8578 1000-8578 |
publishDate |
2019-04-01 |
description |
Objective To investigate the safety and efficacy of the induction therapy of nimotuzumab combined with PF regimen (cisplatin+5-fluorouracil) in the follow-up treatment of locally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy. Methods We included 118 patients with stage Ⅲ-Ⅳa nasopharyngeal carcinoma, 58 cases in NPF group (induction therapy of nimotuzumab combined with PF regimen) and 60 cases in TPF group (induction chemotherapy of docetaxel, cisplatin and fluorouracil regimen). After two cycles of induction therapy, all patients received concurrent cisplatin and intensity-modulated radiotherapy (IMRT), and the safety and short-term efficacy of the two groups were compared. Results Compared with TPF group, NPF induction therapy was more effective for cervical lymph nodes (P=0.036); however, there was no significant difference in the effect of induction therapy on primary lesions, overall effect or the immediate effect of the whole course of treatment(P > 0.05). Compared with TPF group, neutropenia and gastrointestinal reaction in the NPF group was significantly improved during the induction therapy (P=0.028, P=0.049); gastrointestinal reaction, oral mucositis and radiation dermatitis in the NPF group were significantly improved during the concurrent chemoradiotherapy (P=0.038, P=0.041, P=0.035). Conclusion For locally advanced nasopharyngeal carcinoma patients received cisplatin concurrent IMRT, the induction therapy of nimotuzumab combined with PF regimen have a better lymph node remission rate and mild adverse reactions. Patients had better tolerance in subsequent concurrent chemoradiotherapy, but the long-term efficacy requires further follow-up observation. |
topic |
nasopharyngeal carcinoma egfr monoclonal antibody induction treatment efficacy adverse reaction |
url |
http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.2031.htm |
work_keys_str_mv |
AT luying multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT chendagui multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT liangjinhui multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT gaojianquan multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT luozhanxiong multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT wangrensheng multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT liuwenqi multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT huangchangjie multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT ningxuejian multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT liumeilian multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma AT huanghaixin multicenterclinicalstudyofnimotuzumabcombinedwithpfregimenininductiontreatmentoflocallyadvancednasopharyngealcarcinoma |
_version_ |
1724938498761293824 |